Optimized formulation of magnetic chitosan microspheres containing the anticancer agent, oxantrazole
- PMID: 1614973
- DOI: 10.1023/a:1015803321609
Optimized formulation of magnetic chitosan microspheres containing the anticancer agent, oxantrazole
Abstract
A combined emulsion/polymer cross-linking/solvent evaporation technique was used to prepare magnetic chitosan microspheres (MCM) containing the anticancer drug, oxantrazole. A central composite experimental design was used to simultaneously evaluate a variety of formulation factors on a number of response variables, such as the percentage of oxantrazole entrapped in the MCM. In association with the study design, statistical optimization procedures indicated the factors that significantly influence MCM preparation and what levels of the factors are needed to produce optimum MCM. Entrapment of anticancer agents into biodegradable microspheres is difficult because of low aqueous drug solubility and porosity of the particles. The latter effect was circumvented by a chitosan cross-linking step that resulted in approximately 3% (w/w) oxantrazole entrapment in the MCM via the optimization procedures. The combined formulation and statistical optimization strategy provide a basis to develop other microparticulate systems and led to a dosage form that can be used for future in vivo investigations.
Similar articles
-
Targeting anticancer drugs to the brain. I: Enhanced brain delivery of oxantrazole following administration in magnetic cationic microspheres.J Drug Target. 1993;1(1):7-14. doi: 10.3109/10611869308998759. J Drug Target. 1993. PMID: 8069547
-
Optimization of the formulation design of chitosan microspheres containing cisplatin.J Pharm Sci. 1996 Nov;85(11):1204-10. doi: 10.1021/js960092j. J Pharm Sci. 1996. PMID: 8923326
-
Effect of formulation variables on cis-platin loaded chitosan microsphere properties.J Microencapsul. 1999 Nov-Dec;16(6):697-703. doi: 10.1080/026520499288645. J Microencapsul. 1999. PMID: 10575622
-
Chitosan microspheres as a potential carrier for drugs.Int J Pharm. 2004 Apr 15;274(1-2):1-33. doi: 10.1016/j.ijpharm.2003.12.026. Int J Pharm. 2004. PMID: 15072779 Review.
-
Chitosan: properties, preparations and application to microparticulate systems.J Microencapsul. 1997 Nov-Dec;14(6):689-711. doi: 10.3109/02652049709006820. J Microencapsul. 1997. PMID: 9394251 Review.
Cited by
-
Review on the Production of Polysaccharide Aerogel Particles.Materials (Basel). 2018 Oct 31;11(11):2144. doi: 10.3390/ma11112144. Materials (Basel). 2018. PMID: 30384442 Free PMC article. Review.
-
Preparation of biocompatible carboxymethyl chitosan nanoparticles for delivery of antibiotic drug.Biomed Res Int. 2013;2013:236469. doi: 10.1155/2013/236469. Epub 2013 Mar 18. Biomed Res Int. 2013. PMID: 23586023 Free PMC article.
-
Biopolymeric nanoparticles.Sci Technol Adv Mater. 2010 Feb 26;11(1):014104. doi: 10.1088/1468-6996/11/1/014104. eCollection 2010 Feb. Sci Technol Adv Mater. 2010. PMID: 27877319 Free PMC article. Review.
-
Targeting anticancer drugs to the brain: II. Physiological pharmacokinetic model of oxantrazole following intraarterial administration to rat glioma-2 (RG-2) bearing rats.J Pharmacokinet Biopharm. 1993 Oct;21(5):575-92. doi: 10.1007/BF01059115. J Pharmacokinet Biopharm. 1993. PMID: 8145132
-
Preparation of Puerarin Chitosan Oral Nanoparticles by Ionic Gelation Method and Its Related Kinetics.Pharmaceutics. 2020 Mar 2;12(3):216. doi: 10.3390/pharmaceutics12030216. Pharmaceutics. 2020. PMID: 32131425 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources